Print Print    Close Close

Senate investigations panel to probe Mylan's EpiPen pricing

Published September 08, 2016

Reuters
35dc97cb-

A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in Washington (Copyright Reuters 2016)

The U.S. Senate's permanent subcommittee on investigations will probe Mylan Pharmaceuticals' pricing of the allergy auto-injector EpiPen, according to a press release issued on Wednesday.

The release described the probe as a "preliminary inquiry."

Mylan has been criticized - including by Democratic presidential candidate Hillary Clinton - for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies. Mylan raised the price from about $100 in 2008 to about $600 currently. It has offered some discounts but this has done little to allay concerns.

More on this...

  • New York attorney general investigates EpiPen manufacturer
  • Mylan to launch first generic to EpiPen allergy injection
  • How EpiPen’s maker raised prices, and hackles, so much

"Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan's sustained price increases," Senators Rob Portman, the Republican chair of the subcommittee, and Claire McCaskill, the top Democrat, said in a statement.

Mylan did not immediately respond to a request for comment.

Print Print    Close Close

URL

https://www.foxnews.com/health/senate-investigations-panel-to-probe-mylans-epipen-pricing

  • Home
  • Video
  • Politics
  • U.S.
  • Opinion
  • Entertainment
  • Tech
  • Science
  • Health
  • Travel
  • Lifestyle
  • World
  • Sports
  • Weather
  • Privacy
  • Terms

This material may not be published, broadcast, rewritten, or redistributed. © FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Do Not Sell my Personal Information - New Terms of Use - FAQ